Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BoneSource is a synthetic, biocompatible, and osteoconductive bone substitute material composed of hydroxyapatite. It was originally developed by the American Dental Association Health Foundation and is marketed by Stryker. The product consists of a powder mixture of tetracalcium phosphate and dicalcium phosphate anhydrous which, when mixed with a sterile aqueous solution, forms a sculptable paste. This paste sets into a solid hydroxyapatite matrix at body temperature without an exothermic reaction, making it ideal for use near sensitive soft tissues or the brain. It is primarily indicated for the repair of cranial defects, filling of burr holes, and craniofacial reconstruction, where it serves as a scaffold for the inward growth of native bone tissue over time.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BoneSource.